Opthea Q and A, page-4

Also Opthea investment thesis for dummies (like me)

Investment Thesis for Dummies: Why Opthea Might Be a Smart Bet

a) Vision Matters
Nobody likes being blind or facing a reduced quality of life. People want to keep driving, watching TV, and enjoying their daily activities.
.

b) The Problem: Wet AMD
Wet Age-related Macular Degeneration (Wet AMD) is a leading cause of vision loss, particularly as people age, causing a significant decline in central vision.
.

c) The Cost of Treatment
Drugs Are Expensive, especially in the USA. The high costs are due to extensive research, development, and testing required to bring a new drug to market.
.

d) The Treatment Gap
There have been No New Treatment Pathways for Wet AMD in the last 20 years, leaving a significant unmet need for more effective therapies.
.

e) The Opportunity
Any New Drug That Can Safely Improve or Delay the impacts of Wet AMD will be extremely valuable, both to patients and investors.
.

f) The Tipping Point
Opthea is currently In Phase 3 Trials, the final hurdle before potential approval. The company is awaiting readouts from these trials, which could be the tipping point that determines its future success.

g) The Potential
If Opthea’s Phase 3 trials are successful, the company could become incredibly profitable, potentially reaching a market value of AUD $3-5 billion, $2.50~$4.50/share